imiglucerase

GPTKB entity

Statements (59)
Predicate Object
gptkbp:instance_of gptkb:physicist
gptkbp:activities replaces deficient enzyme
gptkbp:appointed_by intravenous infusion
gptkbp:approves gptkb:1994
gptkb:FDA
with sterile water
gptkbp:brand gptkb:Cerezyme
gptkbp:clinical_trial Phase III
long-term therapy
Gaucher disease studies
gptkbp:contraindication hypersensitivity to imiglucerase
gptkbp:developed_by gptkb:Genzyme_Corporation
gptkbp:dosage_form solution for infusion
gptkbp:duration every 2 weeks
lifelong therapy
gptkbp:education adherence to therapy
recognize side effects
gptkbp:excretion urine
gptkbp:formulation lyophilized powder
https://www.w3.org/2000/01/rdf-schema#label imiglucerase
gptkbp:indication gptkb:physicist
acute type 1 Gaucher disease
chronic type 1 Gaucher disease
gptkbp:ingredients glucocerebrosidase
C_12 H_19 N_3 O_9 P
gptkbp:is_atype_of A16 A B02
gptkbp:is_monitored_by liver function tests
hemoglobin levels
spleen size
platelet counts
gptkbp:is_used_for treatment of Gaucher's disease
gptkbp:manager intravenous
gptkbp:marketed_as gptkb:Cerezyme
gptkbp:metabolism lysosomal degradation
gptkbp:name Essential Medicines
gptkbp:pharmacokinetics half-life of 2-3 hours
gptkbp:population adults and children
gptkbp:provides_information_on Gaucher disease management
gptkbp:research_focus gptkb:healthcare_organization
gptkb:physicist
patient outcomes
biotechnology advancements
long-term safety
gptkbp:shelf_life 24 months
gptkbp:side_effect fatigue
headache
nausea
abdominal pain
allergic reactions
fever
rash
joint pain
chills
infusion reactions
gptkbp:storage refrigerated
gptkbp:type recombinant glucocerebrosidase
gptkbp:type_of 57636-09-4
gptkbp:bfsParent gptkb:Cerezyme
gptkbp:bfsLayer 5